Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficac...
Saved in:
| Published in | PloS one Vol. 9; no. 12; p. e111920 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
11.12.2014
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma.
We searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events.
Nine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27-2.01) and 1-year survival (combined RR = 1.26, 95% CI: 1.14-1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR = 1.23, 95% CI: 1.10-1.36), vomiting (combined RR = 1.73, 95% CI: 1.41-2.12) and neutropenia (combined RR = 1.75, 95% CI: 1.42-2.16) compared to the group for DTIC alone.
These data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion. |
|---|---|
| AbstractList | Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma.BACKGROUNDMalignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma.We searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events.METHODSWe searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events.Nine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27-2.01) and 1-year survival (combined RR = 1.26, 95% CI: 1.14-1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR = 1.23, 95% CI: 1.10-1.36), vomiting (combined RR = 1.73, 95% CI: 1.41-2.12) and neutropenia (combined RR = 1.75, 95% CI: 1.42-2.16) compared to the group for DTIC alone.RESULTSNine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27-2.01) and 1-year survival (combined RR = 1.26, 95% CI: 1.14-1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR = 1.23, 95% CI: 1.10-1.36), vomiting (combined RR = 1.73, 95% CI: 1.41-2.12) and neutropenia (combined RR = 1.75, 95% CI: 1.42-2.16) compared to the group for DTIC alone.These data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion.CONCLUSIONThese data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion. Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma. We searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events. Nine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27-2.01) and 1-year survival (combined RR = 1.26, 95% CI: 1.14-1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR = 1.23, 95% CI: 1.10-1.36), vomiting (combined RR = 1.73, 95% CI: 1.41-2.12) and neutropenia (combined RR = 1.75, 95% CI: 1.42-2.16) compared to the group for DTIC alone. These data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion. Background Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma. Methods We searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events. Results Nine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27–2.01) and 1-year survival (combined RR = 1.26, 95% CI: 1.14–1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR = 1.23, 95% CI: 1.10–1.36), vomiting (combined RR = 1.73, 95% CI: 1.41–2.12) and neutropenia (combined RR = 1.75, 95% CI: 1.42–2.16) compared to the group for DTIC alone. Conclusion These data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion. Background Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma. Methods We searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events. Results Nine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27–2.01) and 1-year survival (combined RR = 1.26, 95% CI: 1.14–1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR = 1.23, 95% CI: 1.10–1.36), vomiting (combined RR = 1.73, 95% CI: 1.41–2.12) and neutropenia (combined RR = 1.75, 95% CI: 1.42–2.16) compared to the group for DTIC alone. Conclusion These data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion. Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare the efficacy and safety of DTIC with or without placebo and DTIC-based combination therapies in patients with advanced metastatic melanoma. We searched from electronic databases such as The Cochrane Library, MEDLINE, EBSCO, EMBASE, Ovid, CNKI, and CBMDisc from 2003 to 2013. The primary outcome measures were overall response and 1-year survival, and the secondary outcome measurements were adverse events. Nine randomized controlled trials (RCTs) involving 2,481 patients were included in the meta-analysis. DTIC-based combination therapies was superior to DTIC alone in overall response (combined risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.27-2.01) and 1-year survival (combined RR = 1.26, 95% CI: 1.14-1.39). Patients with DTIC-based combination therapies had higher incidence of adverse events including nausea (combined RR = 1.23, 95% CI: 1.10-1.36), vomiting (combined RR = 1.73, 95% CI: 1.41-2.12) and neutropenia (combined RR = 1.75, 95% CI: 1.42-2.16) compared to the group for DTIC alone. These data suggested that DTIC-based combination therapies could moderately improve the overall response and the 1-year survival but increased the incidence of adverse events. Further large-scale, high-quality, placebo-controlled, double-blind trials are needed to confirm this conclusion. |
| Audience | Academic |
| Author | Jiang, Guan Sun, Chao Li, Rong-Hua Liu, Yan-Qun Zheng, Jun-Nian |
| AuthorAffiliation | 1 Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221002, China Shanghai Jiao Tong University School of Medicine, China 3 Center for Disease Control and Prevention of Xuzhou City, Xuzhou, 221002, China 2 Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, 221002, China |
| AuthorAffiliation_xml | – name: Shanghai Jiao Tong University School of Medicine, China – name: 3 Center for Disease Control and Prevention of Xuzhou City, Xuzhou, 221002, China – name: 2 Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, 221002, China – name: 1 Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221002, China |
| Author_xml | – sequence: 1 givenname: Guan surname: Jiang fullname: Jiang, Guan – sequence: 2 givenname: Rong-Hua surname: Li fullname: Li, Rong-Hua – sequence: 3 givenname: Chao surname: Sun fullname: Sun, Chao – sequence: 4 givenname: Yan-Qun surname: Liu fullname: Liu, Yan-Qun – sequence: 5 givenname: Jun-Nian surname: Zheng fullname: Zheng, Jun-Nian |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25502446$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9uO0zAQhiO0iD3AGyCIhITgosWnOMleIFXlVGlXi2Dh1po4TuoqiYvtLJSnx92mqFmtEMqFR5Nv_vH8yZxGR53pVBQ9xWiKaYrfrExvO2im65CeIoxxTtCD6ATnlEw4QfToID6OTp1bIZTQjPNH0TFJEkQY4yeRewcSbAG_dafiuWmLcJbxNdha-W2wVBbWm_hGWde7-BCeNaFxrLv4M3itOu_in9ov40todN1B5-NL1UBnWjiPZyH2MJmF626cdo-jhxU0Tj0ZzrPo24f31_NPk4urj4v57GIieU78BFd5xbMqxRSlBeVFkaEsKbkkVJaElIrRisuUAQEoSJlilJdFliKEIc2YQik9i57vdNeNcWLwywnMaUJYzrIkEIsdURpYibXVLdiNMKDFbcLYWoD1WjZKsIRySFKGeCIZIjhHrEhlqVKssKLAg9bboVtftKqUwRILzUh0_KbTS1GbG8EIpywlQeDVIGDNj145L1rtpGqCi8r0t_fOWc4ZxgF9cQe9f7qBqiEMoLvKhL5yKypmDGcBZEkeqOk9VHhK1WoZvnGlQ35U8HpUEBivfvkaeufE4uuX_2evvo_ZlwfsUkHjl840vdemc2Pw2aHTfy3e_9UBON8B0hrnrKqE1B62OmE03QiMxHaF9qaJ7QqJYYVCMbtTvNf_Z9kfbjIekA |
| CitedBy_id | crossref_primary_10_1002_advs_202408707 crossref_primary_10_12677_ACM_2022_126761 crossref_primary_10_1186_s12885_018_4479_2 crossref_primary_10_1007_s11095_021_02999_w crossref_primary_10_1016_j_ijpharm_2019_04_063 crossref_primary_10_1021_acs_molpharmaceut_4c00393 crossref_primary_10_1038_s41598_022_11570_5 crossref_primary_10_1186_s12967_023_04200_9 crossref_primary_10_3390_ph17070921 crossref_primary_10_1016_j_ejmech_2015_06_055 crossref_primary_10_1080_1061186X_2024_2362361 crossref_primary_10_1177_1534735421990078 crossref_primary_10_3390_cells12192401 crossref_primary_10_1016_j_tranon_2019_02_007 crossref_primary_10_1371_journal_pone_0150751 crossref_primary_10_1016_j_jddst_2024_106556 crossref_primary_10_3390_ijms26030988 crossref_primary_10_3390_molecules24081516 crossref_primary_10_1038_s41698_022_00326_z crossref_primary_10_3390_ijms21228480 crossref_primary_10_1002_ijc_32648 crossref_primary_10_1186_s13765_022_00743_5 crossref_primary_10_1007_s11938_016_0109_8 crossref_primary_10_1021_acs_molpharmaceut_7b00904 crossref_primary_10_15407_polymerj_46_02_135 crossref_primary_10_1002_cbf_3950 crossref_primary_10_2174_0115733947253349231027043858 crossref_primary_10_1007_s13402_023_00910_w crossref_primary_10_1016_j_ncrna_2024_09_009 crossref_primary_10_1097_CMR_0000000000000890 crossref_primary_10_7555_JBR_36_20210163 crossref_primary_10_2174_2468187313666230825105753 crossref_primary_10_1080_14728222_2021_1956464 crossref_primary_10_1134_S0026893320020144 crossref_primary_10_3390_ijms23147635 crossref_primary_10_1016_j_gendis_2022_02_007 crossref_primary_10_3390_ijms23073586 crossref_primary_10_1016_j_humpath_2019_09_017 |
| Cites_doi | 10.1002/ijc.23052 10.1002/sim.1186 10.1200/JCO.2007.14.8288 10.1038/mt.2013.79 10.1097/00008390-200102000-00009 10.1016/j.ctrv.2013.06.004 10.1016/S1470-2045(13)70237-7 10.3322/canjclin.57.1.43 10.1186/1476-4598-9-69 10.1056/NEJMoa1103782 10.3322/caac.20074 10.1016/j.ejca.2004.04.030 10.1200/JCO.2000.18.1.158 10.1016/j.bbrc.2011.02.042 10.1038/nature05661 10.1158/1078-0432.CCR-04-2353 10.1371/journal.pmed.1000097 10.3109/09546634.2011.579082 10.1371/journal.pmed.1000100 10.1158/1078-0432.CCR-11-0556 10.1038/bjc.2011.183 10.3322/caac.20073 10.1056/NEJMoa1104621 10.1016/j.soncn.2013.06.005 10.3322/caac.21166 10.1038/bjc.2013.298 10.1200/JCO.2006.06.0483 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2014 Public Library of Science 2014 Jiang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2014 Jiang et al 2014 Jiang et al |
| Copyright_xml | – notice: COPYRIGHT 2014 Public Library of Science – notice: 2014 Jiang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2014 Jiang et al 2014 Jiang et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0111920 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection (subscription) ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database (ProQuest) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Agricultural Science Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Dacarbazine Therapies in Malignant Melanoma |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1635249485 oai_doaj_org_article_4536a574065c4021904b7cde71e1e3a6 PMC4263472 3523696051 A418635459 25502446 10_1371_journal_pone_0111920 |
| Genre | Research Support, Non-U.S. Gov't Meta-Analysis Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB PV9 RIG RZL BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM PUEGO AAPBV ABPTK ESTFP |
| ID | FETCH-LOGICAL-c692t-1f9f68f71307b36bb8085d6c23cd22de43f6c74a2aab2d7109db87001a784e073 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Nov 05 00:20:57 EDT 2023 Wed Aug 27 01:15:21 EDT 2025 Thu Aug 21 18:13:45 EDT 2025 Mon Jul 21 11:38:34 EDT 2025 Fri Jul 25 10:29:24 EDT 2025 Tue Jun 17 21:15:06 EDT 2025 Tue Jun 10 20:19:04 EDT 2025 Fri Jun 27 04:52:08 EDT 2025 Fri Jun 27 04:57:05 EDT 2025 Thu May 22 21:22:19 EDT 2025 Mon Jul 21 05:58:33 EDT 2025 Thu Apr 24 23:05:35 EDT 2025 Tue Jul 01 01:49:19 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-1f9f68f71307b36bb8085d6c23cd22de43f6c74a2aab2d7109db87001a784e073 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors have declared that no competing interests exist. Contributed reagents/materials/analysis tools: J. Conceived and designed the experiments: GJ YQL JNZ. Performed the experiments: GJ RHL CS. Analyzed the data: GJ RHL. Wrote the paper: GJ RHL CS. |
| OpenAccessLink | https://www.proquest.com/docview/1635249485?pq-origsite=%requestingapplication% |
| PMID | 25502446 |
| PQID | 1635249485 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1635249485 doaj_primary_oai_doaj_org_article_4536a574065c4021904b7cde71e1e3a6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4263472 proquest_miscellaneous_1639496411 proquest_journals_1635249485 gale_infotracmisc_A418635459 gale_infotracacademiconefile_A418635459 gale_incontextgauss_ISR_A418635459 gale_incontextgauss_IOV_A418635459 gale_healthsolutions_A418635459 pubmed_primary_25502446 crossref_citationtrail_10_1371_journal_pone_0111920 crossref_primary_10_1371_journal_pone_0111920 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-12-11 |
| PublicationDateYYYYMMDD | 2014-12-11 |
| PublicationDate_xml | – month: 12 year: 2014 text: 2014-12-11 day: 11 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2014 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | V Gray-Schopfer (ref7) 2007; 445 ER Plummer (ref6) 2011; 11 ref15 AD Sasse (ref12) 2007; Rev1 C Querfeld (ref5) 2011; 17 DS Rigel (ref1) 2010; 60 C Cui (ref24) 2013; 21 Z Yin (ref17) 2012; 23 RF Kefford (ref20) 2010; 9 PB Chapman (ref30) 2011; 364 C Robert (ref21) 2013; 14 A Jemal (ref26) 2010; 60 KM Rubin (ref27) 2013; 29 C Quirin (ref8) 2007; 121 R Siegel (ref2) 2013; 63 T Crosby (ref11) 2000; 2 J Murrell (ref28) 2013; 39 AM Eggermont (ref9) 2004; 40 DF McDermott (ref19) 2008; 26 A Jemal (ref3) 2007; 57 MR Middleton (ref10) 2000; 18 AY Bedikian (ref18) 2006; 24 M Huncharek (ref29) 2011; 11 S O'Day (ref23) 2011; 105 A Liberati (ref14) 2009; 6 B Sherrill (ref25) 2013; 109 JP Higgins (ref16) 2002; 21 C Robert (ref22) 2011; 364 G Jiang (ref4) 2011; 406 D Moher (ref13) 2009; 6 |
| References_xml | – volume: 121 start-page: 2801 year: 2007 ident: ref8 article-title: Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells publication-title: Int J Cancer doi: 10.1002/ijc.23052 – volume: 21 start-page: 1539 year: 2002 ident: ref16 article-title: Quantifying heterogeneity in a meta-analysis publication-title: Stat Med doi: 10.1002/sim.1186 – volume: 26 start-page: 2178 year: 2008 ident: ref19 article-title: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.8288 – volume: 21 start-page: 1456 year: 2013 ident: ref24 article-title: A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma publication-title: Mol Ther doi: 10.1038/mt.2013.79 – volume: 11 start-page: 75 year: 2011 ident: ref29 article-title: Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials publication-title: Melanoma Res doi: 10.1097/00008390-200102000-00009 – volume: 39 start-page: 833 year: 2013 ident: ref28 article-title: The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: opportunities and unanswered questions publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2013.06.004 – volume: 2 start-page: CD001215 year: 2000 ident: ref11 article-title: Systemic treatments for metastatic cutaneous melanoma publication-title: Cochrane Database Syst Rev – volume: 14 start-page: 733 year: 2013 ident: ref21 article-title: Selumetinib plus DTIC versus placebo plus DTIC as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70237-7 – volume: 57 start-page: 43 year: 2007 ident: ref3 article-title: Cancer statistics, 2007 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.57.1.43 – volume: 9 start-page: 69 year: 2010 ident: ref20 article-title: A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line DTIC chemotherapy publication-title: Mol Cancer doi: 10.1186/1476-4598-9-69 – volume: 364 start-page: 2507 year: 2011 ident: ref30 article-title: Improved survival with vemurafenib in melanoma with BRAF V600E mutation publication-title: N Engl J Med doi: 10.1056/NEJMoa1103782 – volume: 60 start-page: 301 year: 2010 ident: ref1 article-title: The evolution of melanoma diagnosis: 25 years beyond the ABCDs publication-title: CA Cancer J Clin doi: 10.3322/caac.20074 – volume: 40 start-page: 1825 year: 2004 ident: ref9 article-title: Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? publication-title: Eur J Cancer doi: 10.1016/j.ejca.2004.04.030 – volume: 18 start-page: 158 year: 2000 ident: ref10 article-title: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.1.158 – volume: 406 start-page: 311 year: 2011 ident: ref4 article-title: A novel approach to overcome temozolomide resistance in glioma and melanoma: inactivation of MGMT by gene therapy publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2011.02.042 – volume: 445 start-page: 851 year: 2007 ident: ref7 article-title: Melanoma biology and new targeted therapy publication-title: Nature doi: 10.1038/nature05661 – ident: ref15 – volume: 11 start-page: 3402 year: 2011 ident: ref6 article-title: Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-2353 – volume: 6 start-page: e1000097 year: 2009 ident: ref13 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 23 start-page: 449 year: 2012 ident: ref17 article-title: A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole publication-title: J Dermatolog Treat doi: 10.3109/09546634.2011.579082 – volume: 6 start-page: e1000100 year: 2009 ident: ref14 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: PLoS Med doi: 10.1371/journal.pmed.1000100 – volume: 17 start-page: 5748 year: 2011 ident: ref5 article-title: Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-0556 – volume: 105 start-page: 346 year: 2011 ident: ref23 article-title: A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with DTIC in stage IV melanoma publication-title: Br J Cancer doi: 10.1038/bjc.2011.183 – volume: 60 start-page: 277 year: 2010 ident: ref26 article-title: Cancer statistics, 2010 publication-title: CA Cancer J Clin doi: 10.3322/caac.20073 – volume: 364 start-page: 2517 year: 2011 ident: ref22 article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1104621 – volume: 29 start-page: 195 year: 2013 ident: ref27 article-title: Management of primary cutaneous and metastatic melanoma publication-title: Semin Oncol Nurs doi: 10.1016/j.soncn.2013.06.005 – volume: Rev1 start-page: CD005413 year: 2007 ident: ref12 article-title: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma publication-title: Cochrane Database Syst – volume: 63 start-page: 11 year: 2013 ident: ref2 article-title: Cancer statistics, 2013 publication-title: CA Cancer J Clin doi: 10.3322/caac.21166 – volume: 109 start-page: 8 year: 2013 ident: ref25 article-title: Q-TWiST analysis comparing ipilimumab/DTIC vs placebo/DTIC for patients with stage III/IV melanoma publication-title: Br J Cancer doi: 10.1038/bjc.2013.298 – volume: 24 start-page: 4738 year: 2006 ident: ref18 article-title: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.0483 |
| SSID | ssj0053866 |
| Score | 2.3674672 |
| SecondaryResourceType | review_article |
| Snippet | Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma... Background Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for... BACKGROUND: Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for... Background Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e111920 |
| SubjectTerms | Analysis Antineoplastic Combined Chemotherapy Protocols Cancer therapies Care and treatment Chemotherapy Clinical trials Complications and side effects Confidence intervals Dacarbazine Dacarbazine - administration & dosage Dacarbazine - adverse effects Dacarbazine - therapeutic use Dermatology Drugs Hospitals Humans Incidence Laboratories Medical Subject Headings-MeSH Medicine and Health Sciences Melanoma Melanoma - drug therapy Meta-analysis Metastases Metastasis Molecular Targeted Therapy - adverse effects Molecular Targeted Therapy - methods Nausea Neutropenia Patients Physical Sciences Research and Analysis Methods Safety Skin cancer Skin diseases Studies Survival Vomiting |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBAgYhAYe069ixE27lURUkQAKKeoscP0ql3WRFdv8_M7Y32qBK5cAtWk9WyXg88008_oaQF21ZeuV8nXNRuVwAZM21YCx3pWXSGl-wcDz68xd5eiY-nZfnO62-sCYs0gNHxR2JkktdKog7pYFcB-KXaJWxTjHHHNeBbBti3jaZij4YVrGU6aAcV-wozcvhqu_cIXZXr7G_904gCnz9o1eerRb9cBXk_LtycicUndwmtxKGpMfx2ffIDdfdIXtplQ70VaKSfn2XDO-1wQ0FpJCmYFuQBjtLY_U3XkRKAYqlGZuB2h1hvYCXoJcdTcSrA8UvtnQJsP0Ca2fo0i101y_1G6rheq1znehN7pGzkw8_3p3mqc1CbmRdrHPmay8rD9nqXLVctm0FMMxKU3Bji8I6wb00SuhC67awWLtp2wq3q7WqhAMXcZ_MOnimfUIth-jPYbxoveCOaSaU0XMnPCDLis8zwrc6b0ziIMdWGIsmbKwpyEWiChucqSbNVEby8a5V5OC4Rv4tTucoiwza4QewqybZVXOdXWXkKRpDE4-jjn6gORasApAGVp2R50ECWTQ6LNO50JthaD5-_fkPQt-_TYReJiHfgzqMTkcj4J2QnWsieTCRBF9gJsP7aLpbrQwNoO2yCAxAcOfWnK8efjYO459i6V3n-k2QqUUtYQFn5EG0_lGzkI8CxhOgLDVZFxPVT0e6y1-BxBwbBQhVPPwfc_WI3AQcG_g3GTsgs_XvjXsMWHHdPglu4Q-OZWbt priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegvPCCGF_LNsAgJOAhWx07dsILKh_TQCog2FDfIsd2yqQuKUv7_3PnuKFBE_AW1ZcqOd9dfmeff0fIszJNK-WqPOYic7EAyBprwVjsUsukNVXC_PHo6Sd5ciY-ztJZWHBrQ1nlJib6QG0bg2vkR4Ab0sRzmbxe_oyxaxTuroYWGtfJDaQuw5IuNesTLvBlKcNxOa7YUZidw2VTu0PssZ5jl--tz5Fn7e9j82i5aNqrgOef9ZNbH6Tj2-RWQJJ00k39Drnm6jtkJ_hqS18EQumXd0n7ThvcVkAiaQoBAJJhZ-mprwHHi45YgGKBxrql28KTBbwEPa_pl45-taW4bkunAN7nWEFDp26h6-ZCv6ITuF7peENyco-cHb8_fXsSh2YLsZF5sopZlVcyqyBnHauSy7LMAIxZaRJubJJYJ3gljRI60bpMLFZw2jLDTWutMuEgUNwnoxqeaZdQywEDcBhPykpwxzQTyuixExXgy4yPI8I3Oi9MYCLHhhiLwm-vKchIOhUWOFNFmKmIxP1dy46J4x_yb3A6e1nk0fY_NJfzIrhlIVIudaoA1aQGMmlAR6JUxjrFHHNcy4g8RmMoukOpfTQoJoJlYJBg2xF56iWQS6PGYp25Xrdt8eHz9_8Q-vZ1IPQ8CFUNqMPocEAC3gk5ugaSBwNJiAhmMLyLprvRSlv89h24c2POVw8_6YfxT7EAr3bN2svkIpfgxhF50Fl_r1nISgHpCVCWGvjFQPXDkfr8h6cyx3YBQiV7f3-sfXITcKrn12TsgIxWl2v3ELDgqnzkHf4X0NJeOA priority: 102 providerName: ProQuest |
| Title | Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25502446 https://www.proquest.com/docview/1635249485 https://www.proquest.com/docview/1639496411 https://pubmed.ncbi.nlm.nih.gov/PMC4263472 https://doaj.org/article/4536a574065c4021904b7cde71e1e3a6 http://dx.doi.org/10.1371/journal.pone.0111920 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdG98ILYnytYxSDkICHVPVH4hQJoW60DKSOaayob5HjOGVSSUrTSvDC386d86EFDbGXKKrPUXO-s38Xn39HyIvY91Nl06EnZGg9CZDV05Ixz_oJCxKTcuaOR09Pg5OZ_DT35zukrtlaKbC4NrTDelKz9bL_88evd-Dwb13VBsXqTv1Vntk-1k4fcgjid2FtUuiqU9nsK4B3u91LRC1ewAeiOkz3r6e0FivH6d_M3J3VMi-ug6V_Z1deWa4md8mdCmfSUWkYe2THZvfIXuXJBX1V0U2_vk-K99rgpgPSTFOYHiBUtgm9cBnieFPSDlBM39gW9KrwaAkvQS8zelaSsxYUv-rSKUD7BebX0Kld6iz_rt_QEdxvtFdToDwgs8n44vjEq0oxeCYY8o3H0mEahClEtAMViyCOQ4BqSWC4MAnniZUiDYySmmsd8wTzO5M4xC1trUJpYRp5SDoZ_Kd9QhMBCEFAO49TKSzTTCqjB1amgD5DMegSUes8MhVPOZbLWEZu801BvFKqMMKRiqqR6hKv6bUqeTr-I3-Ew9nIIsu2-yFfL6LKaSPpi0D7CjCPbyDOBuwkY2USq5hlVuigS56iMUTlkdVmrohGkoUA5MDyu-S5k0CmjQxTeRZ6WxTRx89fbyD05bwl9LISSnNQh9HV8Ql4J2TwakketiRhvjCt5n003VorRQSI3OeOJQh61uZ8ffOzphkfiul5mc23TmYohwE4eZc8Kq2_0SzErIADJShLtfyipfp2S3b5zRGdYzEBqfjBTZT4mNwGLOs4OBk7JJ3NemufAF7cxD1yS80VXMNjhtfJhx7ZPRqfnp333BeYnpsi8Pp7_AebHm4x |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VcIALorwaKHRBIODgNvuw10FCKFCqhjYF0RTlZtbrdagU7FAnQvwpfiMz6wcxqoBLb1Z2bMWzM7PfeGe_IeRx7PupsmnfEzK0ngTI6mnJmGf9hAWJSTlzx6NHR8H-iXw38Sdr5Gd9FgbLKuuY6AJ1khv8Rr4DuMHnjsvk1fybh12jcHe1bqFRmsWB_fEdUrbi5XAX5vcJ53tvx2_2vaqrgGeCPl94LO2nQZhCctZTsQjiOATUkQSGC5Nwnlgp0sAoqbnWMU-wVDGJQ9yd1SqUFjwCnnuJXIaFt4cepSZNggexIwiq43lCsZ3KGrbneWa3sad7H7uKryx_rktAsxZ05rO8OA_o_lmvubIA7l0n1yrkSgelqa2TNZvdIOtVbCjos4rA-vlNUuxqg9sYSFxNIeBA8m0TOnY153hREhlQLAhZFnRVeDCDl6CnGf1Q0r0WFL8T0xEkC1Os2KEjO9NZ_lW_oAO4XmivJlW5RU4uZBpuk04G_2mD0EQA5hAwzuNUCss0k8ronpUp4NlQ9LpE1DqPTMV8jg04ZpHbzlOQAZUqjHCmomqmusRr7pqXzB__kH-N09nIIm-3-yE_m0ZVGIikLwLtK0BRvoHMHdCYjJVJrGKWWaGDLtlCY4jKQ7BN9IkGkoXgAOBLXfLISSB3R4bFQVO9LIpo-P7Tfwgdf2wJPa2E0hzUYXR1IAPeCTnBWpKbLUmIQKY1vIGmW2uliH77KtxZm_P5ww-bYXwoFvxlNl86mb7sBxA2uuROaf2NZiELBmQpQVmq5Rct1bdHstMvjjod2xNIxe_-_W9tkSv749FhdDg8OrhHrgJGdtyejG2SzuJsae8DDl3ED5zzU_L5oqPNLx7Hmm0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELZGkRAviPFrhcEMAgEPWevYiRMkhAqlWhkdE9tQ34LjOGVSScrSCvGv8ddxlzihQRPwsrcovkTJ-e7yXXz-jpDHseel0qShw0VgHAGQ1VGCMcd4CfMTnbqs3B49OfD3TsS7qTfdID_rvTBYVlnHxDJQJ7nGf-Q9wA2eW3KZ9FJbFnE4HL1afHOwgxSutNbtNCoT2Tc_vkP6VrwcD2Gun7ju6O3xmz3HdhhwtB-6S4elYeoHKSRqfRlzP44DQCCJr12uE9dNjOCpr6VQrlKxm2DZYhIHuFKrZCAMeAfc9xK5LLnH0MfktEn2II74vt2qxyXrWcvYXeSZ2cX-7iF2GF_7FJYdA5rvQmcxz4vzQO-ftZtrH8PRdXLNolg6qMxuk2yY7AbZtHGioM8smfXzm6QYKo1LGkhiTSH4QCJuEnpc1p_jQUVqQLE4ZFXQdeHBHF6Cnmb0sKJ-LSj-M6YTSBxmWL1DJ2ausvyrekEHcLxUTk2wcoucXMg03CadDJ5pi9CEA_7gMO7GqeCGKSakVn0jUsC2Ae93Ca91HmnLgo7NOOZRubQnIRuqVBjhTEV2prrEaa5aVCwg_5B_jdPZyCKHd3kiP5tFNiREwuO-8iQgKk9DFg_ITMRSJ0YywwxXfpfsoDFE1YbYJhJFA8ECcAbwqy55VEogj0eGHjFTq6KIxh8-_YfQ0ceW0FMrlOagDq3s5gx4J-QHa0lutyQhGunW8Baabq2VIvrtt3Blbc7nDz9shvGmWPyXmXxVyoQi9CGEdMmdyvobzUJGDChTgLJkyy9aqm-PZKdfShp1bFUgpHv374-1Q65AnInejw_275GrAJdLmk_GtklnebYy9wGSLuMHpe9T8vmig80vcUeeow |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dacarbazine+Combined+Targeted+Therapy+versus+Dacarbazine+Alone+in+Patients+with+Malignant+Melanoma%3A+A+Meta-Analysis&rft.jtitle=PloS+one&rft.au=Jiang%2C+Guan&rft.au=Li%2C+Rong-Hua&rft.au=Sun%2C+Chao&rft.au=Liu%2C+Yan-Qun&rft.date=2014-12-11&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=9&rft.issue=12&rft_id=info:doi/10.1371%2Fjournal.pone.0111920&rft.externalDBID=IOV&rft.externalDocID=A418635459 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |